AstraZeneca reports positive EMERALD-3 results for HCC

​AstraZeneca has reported positive high-level data from the EMERALD-3 Phase III trial, evaluating Imfinzi plus Imjudo, lenvatinib and TACE in unresectable HCC.

The post AstraZeneca reports positive EMERALD-3 results for HCC appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Bruker unveils MyGenius PRO diagnostics system
Agenus announces Phase II results from gastroesophageal cancer therapy
MSD secures EC approval for Enflonsia to prevent infant RSV infection
Philips secures FDA clearance for Verida spectral CT system
First patient receives JANX014 dose in Janux’s trial for mCRPC

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us